BHV 1200
Alternative Names: BHV-1200Latest Information Update: 28 Mar 2025
At a glance
- Originator Yale University
- Developer Biohaven Labs; Yale University
- Class Antivirals; Immunoglobulins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Parenteral)
- 22 Feb 2021 BHV 1200 is available for licensing as of 22 Feb 2021. https://www.biohavenpharma.com/science-pipeline/resources/collaborations-partnering
- 22 Feb 2021 Preclinical trials in COVID-2019 infections in USA (Parenteral)